ライフサイエンスコーパス: anxiety

1 alizing psychopathology (e.g., depression or anxiety).

2 ced sociability, hyperactivity and increased anxiety.

3 0.86; P = .013), but no difference in QOL or anxiety.

4 nce that is a common symptom of pathological anxiety.

5 the tail is aversive, stimulating stress and anxiety.

6 e NAcSh that could account for the increased anxiety.

7 omplication rates, patient satisfaction, and anxiety.

8 cted therapy-induced improvement in patients anxiety.

9 blasted rats as a whole exhibited increased anxiety.

10 gative aspects of caregiving, depression, or anxiety.

11 se without restricting activities or causing anxiety.

12 e neurogenetic bases of WS as well as social anxiety.

13 sex, anxiety severity, and level of parental anxiety.

14 ophysiological processes, including pain and anxiety.

15 involved in the neural circuitry of fear and anxiety.

16 s well as cognition, social interaction, and anxiety.

17 s potential in counteracting obesity-related anxiety.

18 s and symptoms of arthritis, depression, and anxiety.

19 ease, potentially contributing to heightened anxiety.

20 ture of mental illnesses that involve social anxiety.

21 teralization was more pronounced with higher anxiety.

22 to better understand uncontrollable fear and anxiety.

23 ear stimuli, making it difficult to regulate anxiety.

24 ents from the effect of emotions of fear and anxiety.

25 rotect vulnerable animals in milder tests of anxiety.

26 h these process dysfunctions are specific to anxiety.

27 a transdiagnostic neurobiological marker of anxiety.

28 .2% vs. 13.7%; P < 0.001) and cancer-related anxiety (13.3% vs. 15.0%; P < 0.001).

29 , osteoporosis (2.69, 95% CI 1.35-5.38), and anxiety (2.00, 95% CI 1.11-3.61) were significantly high

30 s 22.1%), depression (29.6% versus 13.0%) or anxiety (25.8% versus 8.4%) disorders during the last ye

31 The risk ratio of depression and anxiety 3 years after admission to ICU was 1.04 (95% CI,

32 f life for patients; 2) surrogate stress and anxiety; 3) optimistic health expectations; 4) poor plan

33 y outcomes were body-mass index (BMI), mood, anxiety, affective regulation, and anorexia nervosa-spec

34 genetic mechanisms underlying depression and anxiety after traumatic experiences.

35 sorder, mood, posttraumatic stress disorder, anxiety, alcohol use disorders, drug use disorders, and

36 effects and risk of new-onset depression and anxiety among adult patients admitted to an ICU.

37 ience, and relate this brain effect to trait anxiety and acutely altered bodily sensations-both of wh

38 nfants exhibited higher levels of separation anxiety and arousal in response to social separation, bu

39 variation in the eCB system for the risk for anxiety and consequences of stress across development an

40 Intervention patients experienced less anxiety and depression (median Hospital Anxiety and Depr

41 The cumulative incidence of anxiety and depression during the 3 years following inte

42 We identified comorbidity of anxiety and depression in landmine or UXO victims in fou

43 tric-based brief behavioral intervention for anxiety and depression is associated with benefits super

44 ress may predispose individuals to increased anxiety and depression later in life.

45 (VFQ-25), mental state with the Hospital and Anxiety and Depression Scale (HADS), and employment with

46 ed lower depression symptoms on the Hospital Anxiety and Depression Scale and Patient Health Question

47 od, PTSD symptoms, and QOL with the Hospital Anxiety and Depression Scale and Patient Health Question

48 d fatigue), psychological distress (Hospital Anxiety and Depression Scale anxiety and depressive symp

49 less anxiety and depression (median Hospital Anxiety and Depression Scale score: 6 versus 9; P=0.015)

50 nal connectivity was associated with greater anxiety and depression symptoms during early adulthood,

51 t knowledge, involvement in valve selection, anxiety and depression, (valve-specific) quality of life

52 in the domains of self-care, usual care, and anxiety and depression, and a lower EuroQol visual analo

53 , feeding, addiction, reward and motivation, anxiety and depression, cardiovascular regulation, pain,

54 activities, health-related quality of life, anxiety and depression, employment status, and use of an

55 6, and 10, we determined patients' levels of anxiety and depression, IBS symptoms, quality of life, a

56 y affecting an array of disorders, including anxiety and depression.

57 development of psychiatric diseases, such as anxiety and depression.

58 highly comorbid with mood disorders, such as anxiety and depression.

59 ant association between glaucoma and each of anxiety and depression.

60 the influence of HCM over the development of anxiety and depression.

61 e as a potential target for the treatment of anxiety and depression.

62 fficiently treat the most commonly occurring anxiety and depressive disorders.

63 tress (Hospital Anxiety and Depression Scale anxiety and depressive symptoms and Global Mood Scale ne

64 tes the cognitive control needed to overcome anxiety and differentiate between old and altered items

65 f our sample was asked to recall emotions of anxiety and fear connected to experiences of violence, w

66 heduled physician visits, lowering patients' anxiety and increasing self-efficacy, but there is insuf

67 tion of CGRP(PBN) neurons prevents lethargy, anxiety and malaise associated with cancer.

68 ood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains.

69 psychological conditions such as depression, anxiety and memory loss.

70 o the placebo condition, delta-9-THC induced anxiety and modulated right amygdala activation while pr

71 ctional Information for Suicidality) and for anxiety and mood (SASS, Simplified Affective State Scale

72 main psychoactive ingredient of cannabis, on anxiety and on amygdala response while processing fearfu

73 meditation training can reduce self-reported anxiety and other dimensions of negative affect.

74 , however, can impair quality of life, as in anxiety and paranoia.

75 n population requires more sedation to allay anxiety and perceptions of discomfort, which may account

76 seen in affective disorders, such as chronic anxiety and post-traumatic stress disorder.

77 ing periods of threat.SIGNIFICANCE STATEMENT Anxiety and posttraumatic stress disorder patients gener

78 range of stress-related disorders, including anxiety and posttraumatic stress disorder.

79 henotype, autonomic dysfunction, depression, anxiety and probable behaviour disorder, but not cogniti

80 type such that the association between trait anxiety and right amygdala-vPFC pathway FA was strongest

81 Anxiety and risk perception were assessed at 6 weeks and

82 High levels of depression, anxiety and social anxiety occurred in all groups; howev

83 rred in all groups; however, the severity of anxiety and social anxiety symptoms varied by onset site

84 Anxiety and stress were significantly higher during the

85 Wave 1 manic episodes and Wave 2 depression, anxiety and substance use disorders controlling for back

86 important for discrimination during elevated anxiety and that overgeneralization may reflect a defici

87 grammes may be associated with reductions in anxiety and unscheduled physician visits and increases i

88 generalized anxiety disorder, or separation anxiety and who received CBT, pharmacotherapy, or the co

89 o assess the association between depression, anxiety, and AD in adults and examine the risk of hospit

90 appear to have a regulatory role in stress, anxiety, and alcohol.

91 nsions measured by the EPDS: depressed mood, anxiety, and anhedonia.

92 of aberrant attentional processing in social anxiety, and anxiety disorders more broadly, have postul

93 w symptoms, that is, sleepiness, depression, anxiety, and cognitive deficits.

94 o 84 years reported lower sleep disturbance, anxiety, and depression, and better cognitive function t

95 atients with IBD are chronic abdominal pain, anxiety, and depression.

96 symptoms more quickly, mitigate concomitant anxiety, and improve antidepressant treatment continuati

97 with higher reported symptoms of depression, anxiety, and post-traumatic stress disorder 1 year after

98 ed the prevalence of symptoms of depression, anxiety, and post-traumatic stress disorder between part

99 clinically significant levels of depression, anxiety, and posttraumatic stress among patients and lev

100 (posttraumatic stress disorder, depression, anxiety, and substance abuse) on this association.

101 Depression, anxiety, and suicidal ideation are more common among AD

102 shRNA AAV vector decreased vocalizations and anxiety- and depression-like behaviors and increased sen

103 spring of LPD mothers consistently displayed anxiety- and depression-like behaviors under acute stres

104 ndition, yet only aged HCM females displayed anxiety- and depression-like behaviors.

105 CUS promoted anxiety- and depressive-like behaviors that were associa

106 CRF pathways modulate longer-lasting fear in anxiety- and trauma-related disorders.

107 Post-traumatic stress disorder and anxiety are more prevalent in the veteran population.

108 cular CGRP, there was no general increase in anxiety as measured in an open-field assay after intrape

109 personality traits of sensation-seeking/low anxiety associated with enhanced alcohol consumption, wh

110 Secondary outcomes included state anxiety at 1 year, risk perception at 6 weeks and 1 year

111 depression, anxiety, suicidal ideation, and anxiety attacks, in adults with and without a history of

112 The study of inflammation in fear- and anxiety-based disorders has gained interest as growing l

113 sociation between inflammation and fear- and anxiety-based symptoms, suggesting that other factors ar

114 risk often show a high sensation-seeking/low-anxiety behavioural phenotype.

115 ility (beta = 0.12, P = .03) and fear and/or anxiety (beta = 0.38, P < .001) were significant indepen

116 efrontal cortex (vPFC) are linked with trait anxiety, but it remains unclear what potential genetic m

117 a terminalis, which plays essential roles in anxiety circuits.

118 tion differentiates whether hyperactivity or anxiety co-occurs with inner ear dysfunction.

119 om baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score.

120 o 3.9 (95% CI = 2.9-5.4) after adjusting for anxiety, depression, and healthcare utilization.

121 and Care Excellence clinical guidelines for anxiety, depression, and OA and was supported by a brief

122 to be comorbid with migraine include asthma, anxiety, depression, and other chronic pain conditions,

123 stently greater benefits in quality of life, anxiety, depression, and spiritual well-being compared w

124 ean differences in disease activity indices, anxiety, depression, perceived stress, and quality-of-li

125 PFC white matter was associated with greater anxiety/depression during late childhood.

126 nction, obesity, dysfunctional breathing and anxiety/depression.

127 vities, 50% for pain/discomfort, and 41% for anxiety/depression.

128 ntly poorer on all measures of intelligence, anxiety/depressive symptoms, and executive function (dif

129 Both anxiety diagnosis and symptom severity were associated w

130 Children aged 5-12 years referred for anxiety difficulties were randomly allocated (1:1), via

131 ermine whether panic disorder or generalized anxiety disorder (GAD) in pregnancy, or medications used

132 raumatic stress disorder (PTSD), generalized anxiety disorder (GAD), panic disorder (PD), and phobias

133 Compared to patients with generalized anxiety disorder (n = 24) and healthy control subjects (

134 Many patients with social anxiety disorder (SAD) experience inadequate symptom rel

135 external threats is a key factor in mood and anxiety disorder aetiology.

136 six unmedicated individuals with generalized anxiety disorder and 32 healthy comparison subjects grou

137 e-contingent music reward therapy for social anxiety disorder designed to reduce attention dwelling o

138 ility significantly decreased adjustment and anxiety disorder diagnoses among their children.

139 Patients with social anxiety disorder exhibit increased attentional dwelling

140 uring feedback, individuals with generalized anxiety disorder relative to healthy subjects showed a r

141 ERN can inform the choice between first-line anxiety disorder treatments and whether the ERN changes

142 step towards improving our understanding of anxiety disorder vulnerability.

143 her parental education and having a comorbid anxiety disorder were protective factors.

144 METHOD: Forty patients with social anxiety disorder were randomly assigned to eight session

145 for full or probable diagnoses of separation anxiety disorder, generalized anxiety disorder, social p

146 feeding and eating disorders, schizophrenia, anxiety disorder, OCD, and most affective disorders also

147 iety disorder, specific phobias, generalized anxiety disorder, or separation anxiety and who received

148 of separation anxiety disorder, generalized anxiety disorder, social phobia, major depression, dysth

149 onfirmed diagnoses of panic disorder, social anxiety disorder, specific phobias, generalized anxiety

150 Patient Health Questionnaire-9, Generalised Anxiety Disorder-7 scale, Alcohol Use Disorder Identific

151 d reinforcement) is disrupted in generalized anxiety disorder.

152 rments during decision making in generalized anxiety disorder.

153 M age=25.8+/-8.5; 67% female) with principal anxiety disorders (n=60) or no lifetime history of Axis

154 al neurobiology of behavioral inhibition and anxiety disorders and may aid in early risk assessment a

155 eCB-based treatment approaches for mood and anxiety disorders and suggest a potentially wider therap

156 Anxiety disorders are associated with disruptions in bot

157 Many anxiety disorders are characterized by generalization of

158 Anxiety disorders are commonly associated with increased

159 herapeutic compounds to treat depression and anxiety disorders in women.

160 At the core of anxiety disorders lies the tendency to generalize fear f

161 ttentional processing in social anxiety, and anxiety disorders more broadly, have postulated an initi

162 -environmental reasons why hyperactivity and anxiety disorders occur at higher rates in deaf individu

163 ertoire of effective treatments for mood and anxiety disorders represents a critical unmet need.

164 depressant effects in patients with mood and anxiety disorders that were previously resistant to trea

165 ctural neuroimaging studies of patients with anxiety disorders utilize adult samples, and the few stu

166 Anxiety disorders were assessed using the Mini-Internati

167 spectrum disorder, substance use disorders, anxiety disorders, and personality disorders.

168 depressive disorder (MDD), bipolar disorder, anxiety disorders, and schizophrenia.

169 hizophrenia, bipolar or unipolar depression, anxiety disorders, and substance use disorders).

170 those with antisocial personality disorder, anxiety disorders, depressive disorders, and a history o

171 the 16 patients had comorbid mood disorders, anxiety disorders, or both.

172 rnalizing conditions of major depression and anxiety disorders, risk was associated with low SA but w

173 -onset obsessive-compulsive disorder and the anxiety disorders, suggest a broad and important role fo

174 ms between posttraumatic stress disorder and anxiety disorders, the latter has received less attentio

175 ic acid (GABA)) neurotransmitter circuits in anxiety disorders, the stress system has been directly i

176 stigation of vmPFC safety signaling in other anxiety disorders, with potential implications for the d

177 ry features of these treatments in pediatric anxiety disorders.

178 has been implicated anxiogenic behaviors and anxiety disorders.

179 goals of therapeutic interventions in human anxiety disorders.

180 ole of Asb1-mediated immune dysregulation in anxiety disorders.

181 We also assessed 14 lifetime DSM-IV mood, anxiety, disruptive behavior and substance disorders bef

182 Symptom burden and anxiety during HCT hospitalization partially mediated th

183 Collectively, the development of anxiety during stress was caused by microglial recruitme

184 receipt of placebo included more depression/anxiety (F1,438 = 5.41; P = .02), more motivation (F1,27

185 1.72) for depression to 1.92 (1.79-2.04) for anxiety; for illicit drug use they ranged from 1.36 (1.2

186 Depression and anxiety frequently accompany the motor manifestations of

187 -event model, including measures of mood and anxiety, general psychosocial functioning, age at mood d

188 The anxiety group had lower activation of the ventromedial p

189 ge of the patient; time-efficiency and staff anxiety had a key role in escalating intervention.

190 both within-subject self-report measures of anxiety (ICC = 0.66) and threat-potentiated task perform

191 hat is fundamentally important for mediating anxiety in a wide variety of animal species.

192 pted circadian rhythms and rhythmic peaks of anxiety in BD suggest a disruption of rhythmic expressio

193 The most pronounced differences were higher anxiety in cervical and laryngeal, lower anxiety in uppe

194 dy examined effect of experimentally induced anxiety in humans on generalization using the behavioral

195 r anxiety in upper cranial and higher social anxiety in laryngeal.

196 uggest that the acute effects of cannabis on anxiety in males are mediated by the modulation of amygd

197 ce administered scopolamine showed increased anxiety in standard behavioural tests.

198 ntial therapeutic targets for depression and anxiety in traditionally treatment-resistant groups, inc

199 her anxiety in cervical and laryngeal, lower anxiety in upper cranial and higher social anxiety in la

200 logical and/or educational interventions for anxiety in varied population types.

201 High anxiety individuals used a suboptimal decision strategy

202 s, trait anxiety scores from the State Trait Anxiety Inventory-Trait Form, and functional connectivit

203 Risk of depression and anxiety is elevated after intensive care.

204 Anxiety is linked to deficits in structural and function

205 Epigenetic regulation in anxiety is suggested, but evidence from large studies is

206 Moreover, the factor structure of spatial anxiety is to date unknown.

207 on or knockdown of GPR171 in the BLA reduces anxiety-like behavior and fear conditioning.

208 is in the open field test revealed increased anxiety-like behavior at subacute and chronic time-point

209 The mutant animals displayed increased anxiety-like behavior in the elevated plus maze and in a

210 these neuroendocrine axes are suppressed and anxiety-like behavior in the elevated plus maze is dampe

211 The role of GPR171 in anxiety-like behavior or fear conditioning was evaluated

212 mic administration of MS0021570_1 attenuates anxiety-like behavior while intra-BLA administration or

213 SERT knockdown in the MRN or DRN produced anxiety-like behavior, as did withdrawal from ShA or LgA

214 is characterized by hyperactivity, decreased anxiety-like behavior, decreased depression-like behavio

215 Finally, Glp1r knockdown reduced anxiety-like behavior, implicating PVN GLP-1 signaling i

216 f); CaMKII) exhibit hyperactivity, decreased anxiety-like behavior, reduced depressive-related behavi

217 usceptible to RSDS display social avoidance, anxiety-like behavior, reduction of body weight, and ele

218 ng impaired cognitive function and increased anxiety-like behavior.

219 nd, and not explained by spatial movement or anxiety-like behavior.

220 ubset of mice we term resilient only display anxiety-like behaviors after RSDS.

221 is capable of increasing both addiction- and anxiety-like behaviors in rats.

222 In contrast, acute 2-AG depletion increased anxiety-like behaviors, which was normalized by selectiv

223 g/day; GD 9 - PND 21) to assess activity and anxiety-like behaviors.

224 reversal of sex differences in activity and anxiety-like behaviors.

225 he BLA, we investigated its role in fear and anxiety-like behaviors.

226 pe, including diminished depression-like and anxiety-like behaviors.

227 ly impairs GABABR activity causing increased anxiety-like behaviour and susceptibility to seizures.

228 odels reliably produced enduring generalized anxiety-like or depression-like behaviors, as well as hy

229 Lastly, corticosterone rescued the anxiety-like phenotype and messenger RNA levels of Ppm1f

230 atergic responses in msPs and attenuates the anxiety-like phenotype.

231 All anxiety measures were moderately heritable (30% to 41%),

232 ere more likely to mention screening-related anxiety (mild: OR, 6.30; 95% CI: 2.48, 15.97; moderate o

233 Here we investigated how observers' trait anxiety modulates M- and P-pathway processing of clear a

234 n, unmedicated individuals with pathological anxiety (n = 25) and matched healthy control subjects (n

235 etite (n = 97; 75.2%), pain (n = 96; 74.4%), anxiety (n = 77; 59.7%), constipation (n = 69; 53.5%), d

236 igh levels of depression, anxiety and social anxiety occurred in all groups; however, the severity of

237 underpin some of the deleterious effects of anxiety on higher-order cognition.

238 l activity levels and show no clear signs of anxiety or depression, but do show clear signs of reduce

239 and severity of alcohol abuse, craving, and anxiety or depressive symptoms) were significant after c

240 ovariates included age, sex, race/ethnicity, anxiety or mood disorders, family history of drug, alcoh

241 of locomotion was independent of measures of anxiety or motor impairment and could be overcome by str

242 underpinning emotion in humans and treating anxiety or other prevalent emotional disorders.

243 ment, activity limitation, or cancer-related anxiety or pain was evaluated as a function of treatment

244 w-onset psychiatrist-diagnosed depression or anxiety or prescriptions for antidepressants or anxiolyt

245 revalence of post-traumatic stress disorder, anxiety, or depression than did control groups in two st

246 t have an impact on weight, activity levels, anxiety, or depression-related behaviors.

247 icate observed behavioral differences in low anxiety (Overall Anxiety Severity and Impairment Scale s

248 y and Impairment Scale score </= 8) and high anxiety (Overall Anxiety Severity and Impairment Scale s

249 or cognitive outcome (P = 0.03), post-stroke anxiety (P = 0.04) and post-stroke depression (P = 0.02)

250 e results suggest that overgeneralization in anxiety patients may be mediated by an inability to recr

251 al disorder level, only circumscribed social anxiety patients showed sustained visuocortical facilita

252 tion study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Que

253 ype, previously associated with lower social anxiety, predicted decreased threat-related amygdala rea

254 ll but statistically significant benefit for anxiety prevention in all populations evaluated.

255 as the most common DSM-IV-oriented scale was anxiety problems (13%, 12-14).

256 ale of the GBB-24 (r = .71; p < .01) and the anxiety (r = .42; p < .01) and depression scales (r = .4

257 The potential anxiety-reducing (anxiolytic) effects of scopolamine cou

258 xpression, may disrupt responses to fear and anxiety regulation in these individuals.

259 EGF treatment is often experienced with some anxiety related to treatment, regardless of the number o

260 (Cln3(Deltaex1-6)) mice and found increased anxiety-related behavior and impaired aversive learning

261 novel environment, together with heightened anxiety-related behavior in a stressful environment.

262 Tests of anxiety-related behavior including central area time in

263 results suggest that, with the exception of anxiety-related behavior, alternate mouse models are req

264 te functional deficits, as well as activity, anxiety-related behavior, learning and memory, socializa

265 CB signaling on the regulation of stress and anxiety-related behaviors both during and after adolesce

266 ic plasticity, spatial memory, and increased anxiety-related behaviors-phenotypes that more closely m

267 f BHB attenuated CUS-induced depressive- and anxiety-related behaviors.

268 ed: rx3-derived ff1b+ neurons, implicated in anxiety-related behaviours, and corticotrophin releasing

269 on-deficit/hyperactivity disorder (ADHD) and anxiety-related disorders occur at rates 2-3 times highe

270 especially those who exhibit hyperactive and anxiety-related symptoms.

271 lted in a significantly greater reduction in anxiety relative to placebo on the LSAS (Time x Treatmen

272 try governing the maladaptive persistence of anxiety remains unclear.

273 s (indexed by reductions in Liebowitz Social Anxiety Scale) and reductions in cortical volume in bila

274 oxygenation level-dependent responses, trait anxiety scores from the State Trait Anxiety Inventory-Tr

275 Mean Hamilton depression and anxiety scores were highest in AN (p<0.0001).

276 ted with diurnal preference and higher Trait-Anxiety scores, supporting a role for PER3 in mood modul

277 Scale score </= 8) and high anxiety (Overall Anxiety Severity and Impairment Scale score >/= 9) group

278 havioral differences in low anxiety (Overall Anxiety Severity and Impairment Scale score </= 8) and h

279 ief therapy, with minimisation for age, sex, anxiety severity, and level of parental anxiety.

280 State anxiety significantly decreased after the OFC.

281 ns that affect prefrontal D3 receptors alter anxiety, social interaction, and reversal learning.

282 Anxiety states were elicited in healthy participants (n

283 d Social Support (MSPSS), (2) The Depression Anxiety Stress Scales (DASS-21), (3) the Liver Disease S

284 mptoms to compare prevalences of depression, anxiety, suicidal ideation, and anxiety attacks, in adul

285 Primary anxiety symptoms (measured by child, parent, or clinicia

286 asured by Diffusion Tensor Imaging (DTI) and anxiety symptoms in a sample of N = 100 monozygotic (gen

287 Cognitive behavioral therapy reduced primary anxiety symptoms more than fluoxetine and improved remis

288 Anxiety symptoms predicted (p</=0.05) bed days at 3, 6,

289 en PM2.5 and current level of depressive and anxiety symptoms using a nationally representative proba

290 however, the severity of anxiety and social anxiety symptoms varied by onset site group.

291 assess the impact of ketamine and placebo on anxiety symptoms.

292 ling for baseline anhedonia, depression, and anxiety symptoms.

293 HRQoL-T1 and anxiety-T2 significantly predicted 72.3 and 61.6% of the

294 ceptibility to stress-related depression and anxiety through effects on threat-related amygdala funct

295 critically regulates stress responsivity and anxiety throughout the life span.

296 eatment: F9,115=2.6, p=0.01) but not the VAS-Anxiety (Time x Treatment: F10,141=0.4, p=0.95).

297 HADS-Anxiety was detected preoperatively in 1 donor.

298 hisia, worsening of schizophrenia, headache, anxiety) were reported in 123 (54%) patients treated wit

299 of children with food allergy have increased anxiety, which may be influenced by healthcare professio

300 ssion were largely consistent with those for anxiety, with the exceptions that insurance status was n